China-based CATUG Biotechnology (Suzhou) Co., Ltd. has entered into a partnership with fellow Suzhou firm PersonGen BioTherapeutics (Suzhou) Co., Ltd. to collaboratively develop in vivo chimeric antigen receptor (CAR)-T cell therapies utilizing CATUG’s mRNA-lipid nanoparticle (LNP) technology for global markets.
As of November 2023, a total of ten CAR-T therapies have received marketing approval worldwide, with China accounting for four of these products. The innovative mRNA-LNP delivery method, combined with the in vivo generation of CAR-T therapy, has demonstrated promising therapeutic effects in animal models. This technology is anticipated to significantly lower the costs and production timelines associated with CAR-T therapies, thanks to its inherent advantages in cost-effectiveness and safety. However, the industry still faces pressing challenges, including limitations related to LNP patents, targeted immune cell delivery, management of high-dose mRNA immunogenicity, dose-response relationship studies, and large-scale GMP production. CATUG Bio currently serves over 130 companies in China and internationally with its mRNA-LNP CDMO services.- Flcube.com
